PHM Pharma Mar, S.A.

65.15USD59.40 EUR · BME-4.50%Mkt Cap: 1.12B USDP/E: 15.11

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, res…

Institutional holders11 on file

Key Statistics

Company
Market Cap1.12B USD
Enterprise Value1.01B USD
Revenue (TTM)260.38M USD
Gross Profit229.37M USD
Net Income (TTM)82.24M USD
Revenue/Share15.02 USD
Last Price65.15 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees505
CountryES
SectorHealthcare
IndustryBiotechnology
ISINES0169501022
Valuation
P/E (Trailing)15.11
P/E (Forward)15.50
PEG0.31
EV/EBITDA16.27
EV/Revenue3.88
P/S4.30
P/B4.33
EPS (TTM)4.31 USD
EPS (Forward)4.19 USD
52W Range
64.162% of range115.38
52W High115.38 USD
52W Low64.16 USD
Profitability
Gross Margin94.46%
Oper. Margin21.26%
EBITDA Margin23.82%
Profit Margin33.87%
ROE29.78%
ROA18.98%
ROIC44.74%
ROCE19.91%
Growth
Revenue Growth52.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF58.27M USD
CapEx (TTM)10.29M USD
FCF Margin8.54%
FCF Yield1.98%
Net Debt-116.51M USD
Net Debt/EBITDA-1.88
Net Debt/FCF-5.24
Balance Sheet
Debt/Equity0.20
Current Ratio2.36
Quick Ratio1.83
Book Value/Sh14.99 USD
Cash/Share11.15 USD
Dividends
Fwd Div Rate1.10 USD
Trail. Div Rate0.00 USD
Div. Yield1.61%
5Y Avg Yield1.14%
Payout Ratio25.46%
Ex-Div DateJul 8, 2026
Pay Date—
Splits
Last Split1:12
Split DateJul 22, 2020
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)108.51 USD
Upside (mean)+66.6%
Target Range87.74 USD – 131.62 USD
87.74+66.6% to mean131.62
# Analysts8
Ownership
Shares Out.17.25M
Float13.40M
Insiders21.89%
Institutions11.13%
Technical
SMA 5076.79 (-15.2%)
SMA 20089.00 (-26.8%)
Beta0.43
S&P 52W Chg12.00%
Avg Vol (30d)31.65K
Avg Vol (10d)36.98K
Technical Indicators
RSI (14)26.2
MACD-1.8981
MACD Signal-1.3843
MACD Hist.-0.5137
BB Upper79.09 USD
BB Middle73.22 USD
BB Lower67.35 USD
BB Width16.03%
ATR (14)2.457 USD
Vol Ratio (20d)2.20x

About Pharma Mar (BME: PHM)

›

Pharma Mar (BME: PHM) is listed on the Bolsa de Madrid, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 505 employees.

The shares were at 59.40 EUR on 19 November 2026, down 24.1% over 52 weeks. Its 52-week range is 58.50 EUR to 105.20 EUR: the price is 43.5% below the high and 1.5% above the low.

At a market capitalisation of 1.02B EUR, it trades at 15.1 times trailing earnings and 15.5 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a discount of 55% for PHM. It pays a dividend yielding 1.61% (it pays out 25% of its earnings), against a median of 0.94% among the dividend payers in that peer group.

Pharma Mar reports return on equity of 29.8%, an operating margin of 21.3% and revenue up 52.6% year over year.

It holds more cash than debt, a net cash position of 106.23M EUR. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 8 analysts cover the stock, with an average rating of Buy; their mean price target of 98.94 EUR is 66.6% above the current price. The next earnings report is expected on 25 February 2027.